Parenterally administrable influenza vaccine and uses thereof
AssigneeCodagenix Inc.
InventorsJohn Robert Coleman, Steffen Mueller, Chen Yang, James W. Harpel
Life of this patent
Estimating the term…
Abstract
The present invention provides for parenterally administrable live attenuated influenza immune compositions. Methods of using parenterally administrable live attenuated influenza immune compositions to elicit an immune response, and particularly, a protective immune response are also provided.
Claims42
A method of eliciting an immune response in a subject in need thereof, comprising:
- parenterally administering a composition comprising a live attenuated influenza virus in which expression of hemagglutinin (HA) and neuraminidase (NA) is reduced compared to a natural isolate virus, wherein the reduction in expression is a result of recoding the HA protein-encoding sequence and recoding the NA protein-encoding sequence, thereby eliciting the immune response in the subject,
- wherein one or both of the HA protein-encoding sequence and the NA protein-encoding sequence on the attenuated influenza virus are recoded by lowering the codon-pair bias of the protein-encoding sequence as compared to the natural isolate virus.
A method of eliciting an immune response in a subject in need thereof, comprising:
- parenterally administering a composition comprising a live attenuated influenza virus in which its hemagglutinin (HA) protein encoding sequence and neuraminidase (NA) protein encoding sequence are recoded compared to its natural isolate virus,
- wherein one or both of the HA protein-encoding sequence and the NA protein-encoding sequence on the attenuated influenza virus are recoded by lowering the codon-pair bias of the protein-encoding sequence as compared to the natural isolate virus, and
- wherein the amino acid sequence of HA protein or NA protein of the live attenuated influenza virus remains the same compared to its natural isolate virus, or
- wherein the amino acid sequence of the HA protein or NA protein of the live attenuated influenza virus comprises up to 20 amino acid substitutions, additions, or deletions compared to the natural isolate virus,
- thereby eliciting the immune response in the subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A live attenuated influenza virus comprising a hemagglutinin (HA) protein encoded by a HA encoding sequence, a neuraminidase (NA) protein encoded by a NA encoding sequence or both, wherein the HA protein encoding sequence comprises SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:15, ORF of SEQ ID NO:15, SEQ ID NO:16, ORF of SEQ ID NO:16, SEQ ID NO:17, or ORF of SEQ ID NO:17 and the NA protein encoding sequence comprises SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:18 or ORF of SEQ ID NO:18.
A parenterally administrable composition, comprising:
- a live attenuated influenza virus in which expression of hemagglutinin (HA) and neuraminidase (NA) is reduced compared to a natural isolate virus, wherein the reduction in expression is a result of recoding the HA protein-encoding sequence and recoding the NA protein-encoding sequence, thereby eliciting the immune response in the subject, or
- a live attenuated influenza virus in which its hemagglutinin (HA) protein encoding sequence and neuraminidase (NA) protein encoding sequence are recoded, and
- wherein the amino acid sequence of HA protein or NA protein of the live attenuated influenza virus remains the same, or wherein the amino acid sequence of the HA protein or NA protein of the live attenuated influenza virus comprises up to 20 amino acid substitutions, additions, or deletions compared to the natural isolate virus;
- and
- a pharmaceutically acceptable carrier or excipient suitable for administration via parenterally administration.
(canceled)
Dependencies are inferred from the claim text.